280 related articles for article (PubMed ID: 23739064)
1. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.
Poirier JT; Dobromilskaya I; Moriarty WF; Peacock CD; Hann CL; Rudin CM
J Natl Cancer Inst; 2013 Jul; 105(14):1059-65. PubMed ID: 23739064
[TBL] [Abstract][Full Text] [Related]
2. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
Reddy PS; Burroughs KD; Hales LM; Ganesh S; Jones BH; Idamakanti N; Hay C; Li SS; Skele KL; Vasko AJ; Yang J; Watkins DN; Rudin CM; Hallenbeck PL
J Natl Cancer Inst; 2007 Nov; 99(21):1623-33. PubMed ID: 17971529
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.
Poirier JT; Reddy PS; Idamakanti N; Li SS; Stump KL; Burroughs KD; Hallenbeck PL; Rudin CM
J Gen Virol; 2012 Dec; 93(Pt 12):2606-2613. PubMed ID: 22971818
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
Rudin CM; Poirier JT; Senzer NN; Stephenson J; Loesch D; Burroughs KD; Reddy PS; Hann CL; Hallenbeck PL
Clin Cancer Res; 2011 Feb; 17(4):888-95. PubMed ID: 21304001
[TBL] [Abstract][Full Text] [Related]
5. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.
Miles LA; Burga LN; Gardner EE; Bostina M; Poirier JT; Rudin CM
J Clin Invest; 2017 Aug; 127(8):2957-2967. PubMed ID: 28650343
[TBL] [Abstract][Full Text] [Related]
6. A Structure-Guided Genetic Modification Strategy: Developing Seneca Valley Virus Therapy against Nonsensitive Nonsmall Cell Lung Carcinoma.
Zhao Z; Cao L; Sun Z; Liu W; Li X; Fang K; Shang X; Hu J; Chen H; Lou Z; Qian P
J Virol; 2023 May; 97(5):e0045923. PubMed ID: 37097154
[TBL] [Abstract][Full Text] [Related]
7. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
8. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.
Jiang T; Collins BJ; Jin N; Watkins DN; Brock MV; Matsui W; Nelkin BD; Ball DW
Cancer Res; 2009 Feb; 69(3):845-54. PubMed ID: 19176379
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Seneca Valley Virus: past perspectives and future directions.
Burke MJ
Oncolytic Virother; 2016; 5():81-9. PubMed ID: 27660749
[TBL] [Abstract][Full Text] [Related]
10. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
11. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
[TBL] [Abstract][Full Text] [Related]
12. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
Ikematsu Y; Tanaka K; Toyokawa G; Ijichi K; Ando N; Yoneshima Y; Iwama E; Inoue H; Tagawa T; Nakanishi Y; Okamoto I
Lung Cancer; 2020 Aug; 146():97-104. PubMed ID: 32526603
[TBL] [Abstract][Full Text] [Related]
13. Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.
Venkataraman S; Reddy SP; Loo J; Idamakanti N; Hallenbeck PL; Reddy VS
Structure; 2008 Oct; 16(10):1555-61. PubMed ID: 18940610
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of a Seneca Valley virus thermostable mutant.
Jayawardena N; McCarthy C; Wang I; Waqqar S; Burga LN; Strauss M; Bostina M
Virology; 2022 Oct; 575():74-82. PubMed ID: 36084546
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study.
Schenk EL; Mandrekar SJ; Dy GK; Aubry MC; Tan AD; Dakhil SR; Sachs BA; Nieva JJ; Bertino E; Lee Hann C; Schild SE; Wadsworth TW; Adjei AA; Molina JR
J Thorac Oncol; 2020 Jan; 15(1):110-119. PubMed ID: 31605793
[TBL] [Abstract][Full Text] [Related]
16. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
17. Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.
Huang F; Ni M; Chalishazar MD; Huffman KE; Kim J; Cai L; Shi X; Cai F; Zacharias LG; Ireland AS; Li K; Gu W; Kaushik AK; Liu X; Gazdar AF; Oliver TG; Minna JD; Hu Z; DeBerardinis RJ
Cell Metab; 2018 Sep; 28(3):369-382.e5. PubMed ID: 30043754
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Assessment of the Health Risk for Livestock When Animal Viruses Are Applied in Human Oncolytic Therapy: A Case Study for Seneca Valley Virus.
Schijven J; Brizee S; Teunis P; de Vos C; Eblé P; Rutjes S
Risk Anal; 2019 May; 39(5):982-991. PubMed ID: 30395685
[TBL] [Abstract][Full Text] [Related]
19. Seneca Valley Virus Suppresses Host Type I Interferon Production by Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage.
Qian S; Fan W; Liu T; Wu M; Zhang H; Cui X; Zhou Y; Hu J; Wei S; Chen H; Li X; Qian P
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566380
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
